3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
2
Carcinoma in Situ
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Hairy Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Burkitt Lymphoma
1
Anus Neoplasms
1
Interventions
Nivolumab
37
pembrolizumab
30
cabozantinib
27
Specimen Handling
25
Magnetic Resonance Spectroscopy
22
Ipilimumab
20
lenvatinib
16
Axitinib
15
belzutifan
13
CTLA-4 Antigen
10
Sunitinib
9
Biopsy
9
Radiosurgery
8
atezolizumab
7
Immunoglobulin G
5
toripalimab
4
fludarabine
4
avelumab
4
aldesleukin
4
Everolimus
4
Disulfides
4
Cyclophosphamide
4
zimberelimab
3
tivozanib
3
spartalizumab
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Diphenhydramine
×
90 days
×
Clear all
No trials found.